WallStreetZenWallStreetZen

NASDAQ: KLRS
Kalaris Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for KLRS

Based on 3 analysts offering 12 month price targets for Kalaris Therapeutics Inc

Min Forecast
$19.00+94.27%
Avg Forecast
$20.67+111.32%
Max Forecast
$23.00+135.17%

Should I buy or sell KLRS stock?

Based on 3 analysts offering ratings for Kalaris Therapeutics Inc.

Strong Buy
Strong Buy
2 analysts 66.67%
Buy
1 analysts 33.33%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although KLRS's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates KLRS as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their KLRS stock forecasts and price targets.

KLRS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-12-23
lockedlocked$00.00+00.00%2025-11-03
lockedlocked$00.00+00.00%2025-09-03

1 of 1

Forecast return on equity

Is KLRS forecast to generate an efficient return?

Company
-84.64%
Industry
356.83%
Market
208.53%
KLRS's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is KLRS forecast to generate an efficient return on assets?

Company
-43.65%
Industry
121.88%
KLRS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

KLRS earnings per share forecast

What is KLRS's earnings per share in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
-$2.47
Avg 2 year Forecast
-$1.60
Avg 3 year Forecast
-$2.54

KLRS revenue forecast

What is KLRS's revenue in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$20.4M
Avg 3 year Forecast
$0.0

KLRS vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
KLRS$9.78$20.67+111.32%Strong Buy
TNXP$15.36N/AN/A
CGEN$1.88$4.00+112.77%Buy
SABS$3.68$10.75+192.12%Strong Buy
PRQR$1.77$4.00+125.99%Strong Buy
View Top Biotech Stocks

Kalaris Therapeutics Stock Forecast FAQ

Is Kalaris Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: KLRS) stock is to Strong Buy KLRS stock.

Out of 3 analysts, 2 (66.67%) are recommending KLRS as a Strong Buy, 1 (33.33%) are recommending KLRS as a Buy, 0 (0%) are recommending KLRS as a Hold, 0 (0%) are recommending KLRS as a Sell, and 0 (0%) are recommending KLRS as a Strong Sell.

If you're new to stock investing, here's how to buy Kalaris Therapeutics stock.

What is KLRS's earnings growth forecast for 2026-2028?

(NASDAQ: KLRS) Kalaris Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 70.9%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.5%.

Kalaris Therapeutics's earnings in 2026 is -$51,708,000.On average, 7 Wall Street analysts forecast KLRS's earnings for 2026 to be -$46,264,171, with the lowest KLRS earnings forecast at -$52,968,988, and the highest KLRS earnings forecast at -$41,238,832. On average, 6 Wall Street analysts forecast KLRS's earnings for 2027 to be -$29,864,021, with the lowest KLRS earnings forecast at -$56,855,351, and the highest KLRS earnings forecast at $12,764,400.

In 2028, KLRS is forecast to generate -$47,595,784 in earnings, with the lowest earnings forecast at -$51,136,151 and the highest earnings forecast at -$43,202,586.

What is KLRS's revenue growth forecast for 2026-2028?

(NASDAQ: KLRS) Kalaris Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 112.2%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 22.95%.

Kalaris Therapeutics's revenue in 2026 is $0.On average, 7 Wall Street analysts forecast KLRS's revenue for 2026 to be $0, with the lowest KLRS revenue forecast at $0, and the highest KLRS revenue forecast at $0. On average, 6 Wall Street analysts forecast KLRS's revenue for 2027 to be $381,529,327, with the lowest KLRS revenue forecast at $0, and the highest KLRS revenue forecast at $1,571,003,112.

In 2028, KLRS is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is KLRS's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: KLRS) forecast ROA is -43.65%, which is lower than the forecast US Biotechnology industry average of 121.88%.

What is KLRS's Price Target?

According to 3 Wall Street analysts that have issued a 1 year KLRS price target, the average KLRS price target is $20.67, with the highest KLRS stock price forecast at $23.00 and the lowest KLRS stock price forecast at $19.00.

On average, Wall Street analysts predict that Kalaris Therapeutics's share price could reach $20.67 by Dec 23, 2026. The average Kalaris Therapeutics stock price prediction forecasts a potential upside of 111.32% from the current KLRS share price of $9.78.

What is KLRS's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: KLRS) Kalaris Therapeutics's current Earnings Per Share (EPS) is -$7.40. On average, analysts forecast that KLRS's EPS will be -$2.47 for 2026, with the lowest EPS forecast at -$2.83, and the highest EPS forecast at -$2.21. On average, analysts forecast that KLRS's EPS will be -$1.60 for 2027, with the lowest EPS forecast at -$3.04, and the highest EPS forecast at $0.68. In 2028, KLRS's EPS is forecast to hit -$2.54 (min: -$2.73, max: -$2.31).

What is KLRS's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: KLRS) forecast ROE is -84.64%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.